DDInter1835 DDInter1657
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Topotecan {u} (Compound) treats {v} (Disease) peripheral nervous system neoplasm
Topotecan {u} (Compound) binds {v} (Gene) TOP1
Topotecan {u} (Compound) upregulates {v} (Gene) ALDH5A1
Topotecan {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Topotecan {u} (Compound) downregulates {v} (Gene) CCNF
Topotecan {u} (Compound) causes {v} (Side Effect) Mucosal inflammation
Topotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Topotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Topotecan (Compound) treats peripheral nervous system neoplasm (Disease)
Topotecan (Compound) binds TOP1 (Gene)
Topotecan (Compound) upregulates ALDH5A1 (Gene)
Topotecan (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Topotecan (Compound) downregulates CCNF (Gene)
Topotecan (Compound) causes Mucosal inflammation (Side Effect)
Topotecan may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Topotecan may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel